A system of check and balances in the blood
How Hematopoietic Stem Cells manage to switch between activation and dormancy

Vienna, May 24th, 2018

Hematopoietic Stem Cells (HSCs) give rise to blood and immune cells of the body, and are therefore essential for our survival. They are in a dormant state, but whenever new blood needs to be formed, such as after blood loss or chemotherapy, they are rapidly activated to compensate for the loss. After completing their mission, they need to go back to their dormant state. The group of Manuela Baccarini at the Max F. Perutz Laboratories, a joint venture of the University of Vienna and the Medical University of Vienna, has now shown how intracellular signalling can safeguard this delicate balance between activation and dormancy. Their results are published in the prominent journal *Cell Stem Cell*.

Blood is the juice of life, as while circulating through the body it delivers vital substances such as oxygen and nutrients to cells and tissues. Chemotherapy, radiotherapy and blood loss in general impoverish the system. A special kind of cells in the bone marrow, called hematopoietic stem cells (HSCs) is able to replenish the impoverished system by giving rise not only to red blood cells, but also to cells of the immune system. Thus, HSCs play an absolutely crucial role for survival.

To compensate for blood loss, HSCs, which are usually dormant, start to actively self-renew and differentiate into all blood cell types. After completing their task, however, HSCs need to revert back to their dormant state very rapidly, or they will exhaust. This requires a very delicate balance. A small tilt towards activation or dormancy can have catastrophic consequences for the organism, resulting, in the worst case, in death.

Manuela Baccarini’s group at the MFPL has now discovered the mechanism behind this delicate balance. First author Christian Baumgartner clarifies: “Up until now, we knew that the balance between activation and return to dormancy existed and was essential, but not how it was kept and which players were involved”.

The new paper identifies the players and details their regulation during stress-induced blood production. “Two pivotal intracellular signalling pathways, almost always activated in parallel, are coordinated by a feedback loop that keeps HSCs in perfect balance. The beauty of it is that the system will be reset irrespectively of the stimulus that initiated it,” says Manuela Baccarini.

To prove this, the group deliberately removed one of the players from the feedback loop and found that the entire balance was shifted, resulting in unrestrained HSC activation, exhaustion of the HSC compartment, and ultimately in the failure to produce enough blood cells to compensate for the loss.

Inhibitors of the pathway at study are currently being used in cancer therapy. The work of the Baccarini now shows that these compounds could be repurposed to mobilize “lazy” HSCs, as seen for instance in ageing organisms.

**Publication in Cell Stem Cell**

Christian Baumgartner, Stefanie Toifl, Matthias Farlik, Florian Halbritter, Ruth Scheicher, Irmgard Fischer, Veronika Sexl, Christoph Bock, and Manuela Baccarini: "**AN ERK-DEPENDENT FEEDBACK MECHANISM PREVENTS HEMATOPOIETIC STEM CELL EXHAUSTION.**" Published online in Cell Stem Cell
PRESS RELEASE

DOI: 10.1016/j.stem.2018.05.003

Scientific contact
Univ.-Prof. Dr. Manuela Baccarini
Max F. Perutz Laboratories
Universität Wien
Vienna BioCenter
1030 Wien, Dr.-Bohr-Gasse 9
T +43-1-4277-546 07
manuela.baccarini@univie.ac.at

Press Contact
Caterina Purini, MSc.
Max F. Perutz Laboratories, Communications
Vienna Biocenter
1030 Wien, Dr.-Bohr-Gasse 9
T +43-1-4277-240 14
M +43-664-602 77-24014
caterina.purini@mfpl.ac.at

About the MFPL
The Max F. Perutz Laboratories (MFPL) are a center established by the University of Vienna and the Medical University of Vienna to provide an environment for excellent, internationally recognized research and education in the field of Molecular Biology. The MFPL are located at the Vienna BioCenter, one of the largest Life Sciences clusters in Austria, and host on average 60 independent research groups, involving more than 500 people from 40 nations.